Loading…

Synthesis and Phase Transformation Studies of Dysprosium-Doped Bi4V2O11 Nanoparticles and Their Application in Visible Light Photocatalytic Degradation of Tetracycline Drug

Recently, Bi4V2O11 as an electrolyte material has pulled in considerable consideration because of its remarkable novel applications. In this article, novel, dysprosium-doped (x = 0.2, 0.3, 0.4, and 0.5) Bi4V2O11 (Dy/BVO) nanoparticles have been synthesized by sol–gel strategy. The photocatalyst Dy/B...

Full description

Saved in:
Bibliographic Details
Published in:ACS omega 2018-09, Vol.3 (9), p.11300-11306
Main Authors: Naqvi, Faria K, Faraz, Mohd, Beg, Saba, Khare, Neeraj
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, Bi4V2O11 as an electrolyte material has pulled in considerable consideration because of its remarkable novel applications. In this article, novel, dysprosium-doped (x = 0.2, 0.3, 0.4, and 0.5) Bi4V2O11 (Dy/BVO) nanoparticles have been synthesized by sol–gel strategy. The photocatalyst Dy/BVO nanoparticles exhibit higher photocatalytic efficiency than BVO nanoparticles assessed by debasement of tetracycline drug under visible light illumination. Our work focuses on the phase transformation, conducting properties, and mechanisms of the Dy/BVO nanoparticles in relation to execute some methods of processing and manufacturing product in commercial applications. The characterization of Dy/BVO was performed by Fourier transform infrared, X-ray diffraction, scanning electron microscopy, energy-dispersive X-ray analysis, and UV–vis analysis. ac impedance spectroscopy was used to analyze the conducting behavior of synthesized nanoparticles in the temperature range 100–600 °C. The photocatalytic activity revealed that Dy/BVO remarkably enhanced the photocatalytic activity. This is the first report that Dy/BVO can destroy the drug effluent which is coming from the drug industry and also worried about the human health hazards.
ISSN:2470-1343
2470-1343
DOI:10.1021/acsomega.8b01012